Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-complex protein 1 subunit zeta-2 (CCT6B) is a molecular chaperone and a component of the chaperonin-containing TCP1 complex (also called TRiC). This complex consists of two rings, each with eight unique subunits, which function collaboratively to fold newly synthesized polypeptides such as actin and tubulin in an ATP-dependent manner. CCT6B is expressed in various tissues, including testis, and plays a role in protein folding, cytoskeletal organization, and potentially tissue-specific processes. While most CCT subunits are overexpressed in several cancers and linked to poor prognosis, CCT6B paradoxically shows reduced expression in hepatocellular carcinoma, and higher levels predict better patient survival, highlighting a unique role among chaperonin subunits[1][2][3].
No specific drugs directly targeting CCT6B; mechanism would theoretically be modulation of protein folding or chaperone activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-complex protein 1 subunit zeta-2 (CCT6B).